CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced new
preclinical data confirming the efficacy of its apelin agonist
peptides in a preclinical model of acute respiratory distress
syndrome (ARDS). The company expects the apelin agonists to have
potential to treat COVID-19 associated ARDS as well as ARDS
patients in general, of which there are approximately three million
globally.
“These new positive preclinical results confirm previous data
showing CB5064 Analogs reduce fluid accumulation and
pro-inflammatory cytokine secretion, key processes underlying the
lethal consequences of severe ARDS and COVID-19 associated ARDS,”
said Kenneth C. Cundy, PhD, CohBar’s Chief Scientific Officer. “By
engaging the apelin pathway, CohBar’s novel approach has the
potential to treat ARDS and COVID-19 associated ARDS, while also
reducing the global damage caused by a cytokine storm that reaches
beyond the lungs to other organs such as the kidneys, liver, and
heart. We plan to complete additional ongoing studies and submit
the combined data for presentation at a future scientific
meeting.”
In the preclinical study, acute lung injury was induced in mice
by administration of lipopolysaccharide (LPS), a bacterial toxin
that produces similar symptoms to other causes of ARDS, including
fluid accumulation and cytokine secretion. A single dose of CB5064
Analog was administered one hour prior to the LPS exposure and
effects on lung weight and levels of pro-inflammatory cytokines
were measured at 4 hours after LPS exposure. Treatment with CB5064
Analogs reduced fluid accumulation in the lungs and a corresponding
broad reduction in levels of key pro-inflammatory cytokines
secreted into the lung fluid, when compared to treatment with a
placebo control.
“ARDS is a major unmet medical need and there are no approved
therapeutics for this devastating condition,” stated Professor Toby
Maher, Director of Interstitial Lung Disease and Professor of
Medicine at the Keck School of Medicine, University of Southern
California. “The data for CohBar’s apelin agonists in this
preclinical model are encouraging and support further advancement
of the program towards candidate selection for clinical
testing.”
Further details of these new data will be available on the
CohBar website at www.cohbar.com.
About the Apelin Receptor and Apelin
The apelin receptor is broadly expressed and abundant in lung
tissue and published preclinical studies have shown that apelin
signaling can reduce the severity of acute lung injury, by reducing
lung fluid accumulation, hypoxemia, and cytokine secretion, which
also occur in COVID-19 associated ARDS and lead to downstream
injury to kidney, heart, and other organs.
Apelin is an endogenous peptide released by fat cells that
activates the apelin receptor, a key cell surface receptor involved
in protective regulation of fluid homeostasis, cardiovascular
function, and metabolism. In addition to its protective effects in
lung injury, apelin has also been shown to reduce body weight and
improve insulin sensitivity in obese mice. Published clinical
reports show that obesity and diabetes are major underlying risk
factors in severe COVID-19, with a mortality rate of 7.8% in
patients with type 2 diabetes versus 2.7% in patients without this
comorbidity.
About ARDS
In addition to COVID-19, ARDS can be triggered by viral or
bacterial pneumonia, sepsis, trauma or other events and represents
a major cause of morbidity and mortality. There is an unmet need
for a safe and effective treatment of ARDS due to its high
mortality rate and lack of effective drug treatments. It also
prolongs hospital stays and requires convalescence in the hospital
and rehabilitation. An effective therapy would reduce time on
ventilators and in the ICU, reduce mortality, and improve quality
of life. ARDS affects approximately three million patients
globally.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company
focused on the research and development of mitochondria based
therapeutics, an emerging class of drugs for the treatment of
chronic and age-related diseases. Mitochondria based therapeutics
originate from the discovery by CohBar’s founders of a novel group
of naturally occurring peptide sequences within the mitochondrial
genome, some of which have been shown to have the
potential to regulate key processes
in multiple systems and organs in the body. To date,
the company has discovered more than 100 mitochondrial derived
peptides and generated over 1,000 analogs. CohBar’s efforts focus
on the development of these peptides into therapeutics that offer
the potential to address a broad range of diseases because of
the underlying impact of mitochondrial dysfunction. The company’s
lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b
clinical trial for NASH and obesity. In addition, CohBar has
four preclinical programs: CB5138 Analogs for fibrotic
diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5
Analogs for CXCR4-related cancer and orphan diseases, and MBT3
Analogs for cancer immunotherapy.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking
statements which are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding anticipated outcomes of research
and clinical trials for our mitochondria based therapeutic (MBT)
candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies,
including but not limited to in the treatment of IPF. You are
cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials; our possible inability to mitigate the prevalence and/or
persistence of the injection site reactions, receipt of unfavorable
feedback from regulators regarding the safety or tolerability of
CB4211 or the possibility of other developments affecting the
viability of CB4211 as a clinical candidate or its commercial
potential; results that are different from earlier data results
including less favorable than and that may not support further
clinical development; our ability to raise additional capital when
necessary to continue our operations; our ability to recruit and
retain key management and scientific personnel; the risk that our
intellectual property may not be adequately protected; our ability
to establish and maintain partnerships with corporate and industry
partners; and risks related to the impact on our business of the
COVID-19 pandemic or similar public health crises. Additional
assumptions, risks and uncertainties are described in detail in our
registration statements, reports and other filings with the
Securities and Exchange Commission and applicable Canadian
securities regulators, which are available on our website,
and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of
future performance and that our actual results may differ
materially from those set forth in the forward-looking statements.
The forward-looking statements and other information contained in
this news release are made as of the date hereof and CohBar does
not undertake any obligation to update publicly or revise any
forward-looking statements or information, whether as a result of
new information, future events or otherwise, unless so required by
applicable securities laws. Nothing herein shall constitute an
offer to sell or the solicitation of an offer to buy any
securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024